Literature DB >> 19221702

[Cutaneous malignant peripheral nerve sheath tumor in neurofibromatosis type 1].

V Dietrich1, J Schaller, J Kunze.   

Abstract

Patients with neurofibromatosis have an increased risk of developing malignant tumors in comparison to the general population. We describe a woman who developed a malignant peripheral nerve sheath tumor in a pre-existing neurofibroma.

Entities:  

Mesh：

Year:  2009        PMID： 19221702     DOI： 10.1007/s00105-008-1700-2

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


  9 in total

1.  Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases.

Authors:  B S Ducatman; B W Scheithauer; D G Piepgras; H M Reiman; D M Ilstrup
Journal:  Cancer       Date:  1986-05-15       Impact factor: 6.860

Review 2.  Farnesyltransferase inhibitors: potential role in the treatment of cancer.

Authors:  A D Cox
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.

Authors:  R E Ferner; J D Lucas; M J O'Doherty; R A Hughes; M A Smith; B F Cronin; J Bingham
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-03       Impact factor: 10.154

4.  Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group.

Authors:  J M Coindre; P Terrier; L Guillou; V Le Doussal; F Collin; D Ranchère; X Sastre; M O Vilain; F Bonichon; B N'Guyen Bui
Journal:  Cancer       Date:  2001-05-15       Impact factor: 6.860

5.  International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis.

Authors:  Rosalie E Ferner; David H Gutmann
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

6.  Malignant peripheral nerve sheath tumors of the skin.

Authors:  E George; P E Swanson; M R Wick
Journal:  Am J Dermatopathol       Date:  1989-06       Impact factor: 1.533

7.  Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.

Authors:  Jonathan W Wojtkowiak; Farid Fouad; Daniel T LaLonde; Miriam D Kleinman; Richard A Gibbs; John J Reiners; Richard F Borch; Raymond R Mattingly
Journal:  J Pharmacol Exp Ther       Date:  2008-03-26       Impact factor: 4.030

Review 8.  Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective.

Authors:  Rosalie E Ferner
Journal:  Lancet Neurol       Date:  2007-04       Impact factor: 44.182

9.  Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Authors:  A Santoro; T Tursz; H Mouridsen; J Verweij; W Steward; R Somers; J Buesa; P Casali; D Spooner; E Rankin
Journal:  J Clin Oncol       Date:  1995-07       Impact factor: 44.544
  9 in total
  1 in total

1.  Soft tissue sarcoma in neurofibromatosis type 1: A rare case of malignant peripheral nerve sheath tumor of the skin.

Authors:  Young Hun Chung; Jin Woo Jang; Jae Young Cho
Journal:  Arch Plast Surg       Date:  2020-01-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.